Stocktoria
Eledon Pharmaceuticals, Inc. ELDN
Eledon Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | $0 |
| R&D expense | $66.3M | $52.0M | $30.3M | $27.1M | $23.7M | $6.1M | $8.1M | $6.8M | $2.0M | $3.2M |
| Operating income | — | — | -$43.0M | -$88.4M | -$36.9M | -$18.5M | -$16.1M | -$14.1M | -$13.1M | -$5.1M |
| Income tax | $35,000 | $431,000 | $0 | $0 | -$2.4M | -$404,000 | — | — | — | $0 |
| Net income | -$45.6M | -$36.2M | -$116.5M | -$88.0M | -$34.5M | -$22.8M | -$16.0M | -$14.1M | -$13.1M | -$5.7M |
| EPS (diluted) | $-0.52 | $-0.66 | $-4.73 | $-6.16 | $-2.33 | — | — | — | — | — |
| Operating cash flow | -$62.3M | -$47.3M | -$39.5M | -$28.4M | -$28.9M | -$15.2M | -$13.9M | -$11.9M | -$14.9M | -$4.9M |
| Free cash flow | — | — | — | — | — | — | — | — | — | -$4.9M |
| Cash & equivalents | $22.8M | $20.5M | $4.6M | $56.4M | $84.8M | $114.2M | $8.8M | $13.0M | $17.2M | $1.1M |
| Total assets | $169.0M | $177.4M | $89.1M | $92.8M | $170.5M | $197.2M | $10.9M | $17.0M | $20.9M | $1.2M |
| Total liabilities | $32.2M | $59.3M | $81.9M | $8.6M | $6.6M | $6.6M | $1.5M | $2.5M | $1.4M | $3.9M |
| Shareholders' equity | $81.1M | $62.4M | -$48.5M | $84.2M | $164.0M | $190.6M | $9.5M | $14.5M | $19.5M | -$2.7M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.